Literature DB >> 28296011

Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.

Andrew P Wright1, Robert J Fontana1, Ryan W Stidham1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28296011      PMCID： PMC5478463          DOI： 10.1002/lt.24757

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


× No keyword cloud information.
  5 in total

1.  Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.

Authors:  A B Mohabbat; W J Sandborn; E V Loftus; R H Wiesner; D H Bruining
Journal:  Aliment Pharmacol Ther       Date:  2012-07-10       Impact factor: 8.171

2.  Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series.

Authors:  Tiong Yeng Lim; Polychronis Pavlidis; Shraddha Gulati; Tasneem Pirani; Mark Samaan; Guy Chung-Faye; Patrick Dubois; Peter Irving; Michael Heneghan; BuʼHussain Hayee
Journal:  Inflamm Bowel Dis       Date:  2016-10       Impact factor: 5.325

3.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Authors:  Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan
Journal:  Gut       Date:  2016-02-18       Impact factor: 23.059

5.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28
  5 in total
  4 in total

1.  Safety of vedolizumab in liver transplant recipients: A systematic review.

Authors:  Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato
Journal:  United European Gastroenterol J       Date:  2019-06-20       Impact factor: 4.623

Review 2.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.

Authors:  Robert Battat; Christopher Ma; Vipul Jairath; Reena Khanna; Brian G Feagan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

3.  Infliximab-Induced Acute Liver Failure in a Patient With Crohn's Disease Requiring Orthotopic Liver Transplantation.

Authors:  Muhammed Mustafa Alikhan; Emad Mansoor; Sagarika Satyavada; Katarina Greer; Wei Xin; Stanley Cohen; Gregory Cooper; Jeffry Katz
Journal:  ACG Case Rep J       Date:  2021-05-14

4.  Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Authors:  Stefan Schreiber; Axel Dignass; Laurent Peyrin-Biroulet; Greg Hather; Dirk Demuth; Mahmoud Mosli; Rebecca Curtis; Javaria Mona Khalid; Edward Vincent Loftus
Journal:  J Gastroenterol       Date:  2018-06-04       Impact factor: 7.527
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.